Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.60 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.60 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.60 |
| ▸ | IGF2R | P11717 | 7/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14363644 | 1.00 | LGALS8 (0.60) | LGALS8LGALS3LGALS4IGF2RMAPK1 | |
| SCHEMBL6685258 | 1.00 | LGALS8 (0.60) | LGALS8LGALS3LGALS4IGF2RMAPK1 | |
| SCHEMBL7904801 | 1.00 | LGALS8 (0.60) | LGALS8LGALS3LGALS4IGF2RMAPK1 | |
| SCHEMBL22817555 | 1.00 | LGALS8 (0.60) | LGALS8LGALS3LGALS4IGF2RMAPK1 | |
| SCHEMBL25480881 | 1.00 | LGALS8 (0.60) | LGALS8LGALS3LGALS4IGF2RMAPK1 | |
| SCHEMBL7904804 | 1.00 | LGALS8 (0.60) | LGALS8LGALS3LGALS4IGF2RMAPK1 | |
| SCHEMBL24014792 | 1.00 | LGALS8 (0.60) | LGALS8LGALS3LGALS4IGF2RMAPK1 | |
| SCHEMBL21878965 | 1.00 | LGALS8 (0.60) | LGALS8LGALS3LGALS4IGF2RMAPK1 | |
| SCHEMBL21934523 | 1.00 | LGALS8 (0.60) | LGALS8LGALS3LGALS4IGF2RMAPK1 | |
| SCHEMBL20904130 | 1.00 | LGALS8 (0.60) | LGALS8LGALS3LGALS4IGF2RMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178512-B2 | Methods and compositions for treating diseases and disorders associated with siglec-8. | JOHNS HOPKINS UNIVERSITY (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110046078-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH SIGLEC-8 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-24 | — | — | US | disclosed |
| US-7745421-B2 | Methods and compositions for treating diseases and disorders associated with Siglec-8 expressing cells | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-06-29 | — | — | US | disclosed |
| US-7700701-B2 | Water-soluble polymer compound having sugar chains | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20080139485-A1 | Methods and Compositions For Treating Diseases and Disorders Associated With Siglec-8 Expressing Cells | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-06-12 | — | — | US | disclosed |
| US-20060287457-A1 | Sugar chain-containing water-soluble polymer compound | NISHIMURA, SHIN-ICHIRO, MR. (JP) | 2006-12-21 | — | — | US | disclosed |
| WO-2005116088-A2 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH SIGLEC-8 EXPRESSING CELLS | THE JOHNS HOPKINS UNIVERSITY (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046078-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH SIGLEC-8 | SIGLEC7, SIGLEC9, FUT8 | LGALS8 4/4885LGALS3 46/4885LGALS4 95/4885 |
| US-20080139485-A1 | Methods and Compositions For Treating Diseases and Disorders Associated With Siglec-8 Expressing Cells | SIGLEC7, SIGLEC9, FUT8 | LGALS8 5/4885LGALS3 56/4885LGALS4 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.